Home page feature | Reading Time 2 minutes

Lallemand purchases Biotec BetaGlucans AS from ArticZymes Technologies ASA

Lallemand Inc’s subsidiary, Danstar Ferment AG has signed an agreement to purchase Biotec BetaGlucans AS (BBG), a wholly owned subsidiary of the ArticZymes Technologies ASA (AZT) company, effective December 31, 2020.

AZT is a publicly listed company located in Tromsø, Norway. BBG is specialized in the development, production and sales of high purity beta-glucan products, from yeast cell walls, sold as immune ingredients for human health supplements and in aquaculture. BBG’s high purity yeast beta-glucan technology and patented soluble beta-glucan (SBG) offer potential for several other applications and markets.

The acquisition includes a specialized pharma and food grade certified production plant located in Tromsø, Northern Norway with an experienced team. Under the terms of the agreement, Lallemand will acquire all of the BBG assets and associated intellectual property including the M-Gard®, SBG®, M-Glucan® and Woulgan® branded product portfolios, and will assume manufacturing responsibilities for beta-glucans in the Nordøya, Tromsø manufacturing facility.

The BBG business is an excellent strategic fit for Lallemand, a global leader in the development, production and marketing of yeast, bacteria and specialty ingredients. President and CEO of Lallemand Inc., Antoine Chagnon commented: “Our acquisition of the Biotec BetaGlucans business will broaden our beta-glucans product portfolio as well as our access to leading technologies within yeast-based ingredients. We look forward to offering our customers in both human and animal nutrition sectors innovative products from Biotec BetaGlucans. We are delighted to have secured the pharma certified Tromsø plant, our first production facility in Norway.”

AZT CEO, Jethro Holter said: “We are delighted to divest BBG to Lallemand who is ideally suited to take over this business. AZT will subsequently become a pure enzyme company with all efforts focused towards expanding it enzymes portfolio through organic and inorganic growth initiatives.”